The World Health Organization (WHO) has again announced the discontinuation of the hydroxychloroquine and lopinavir/ritonavir, for the treatment of hospitalised patients with COVID-19.
It said results from its solidarity trial arm with hydroxychloroquine and a combination of the HIV drugs, produced little or no reduction in mortality (death).
The Solidarity Trial’s International Steering Committee therefore recommended the discontinuation of trials with hydroxychloroquine and lopinavir/ritonavir.
It however said its decision will not affect any other studies of how the treatments can be used as a pre- or post-exposure drug or by patients not in hospitals.
A statement by WHO said, “WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms.
“The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for hospitalized patients.
“The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the 1-2 July WHO Summit on COVID-19 research and innovation.
“These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect.”
Thenation.
0 Comments